NRC-2694-A

NRC-2694-A is an orally effective EGFR tyrosine kinase inhibitor. NRC-2694-A can be used in the study of malignant squamous cell carcinoma (HNSCC) [1].

Product Specifications

CAS Number

[1172626-99-1]

UNSPSC

12352005

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nrc-2694-a.html

Smiles

COC1=CC2=NC=NC(NC3=CC=CC(C#C)=C3)=C2C=C1OCCCN4CCOCC4.Cl

Molecular Formula

C24H27ClN4O3

Molecular Weight

454.95

References & Citations

[1]Adkins D, et al. Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI) : A multi-center, single-arm, phase 2 trial. 2023.